Hemagglutination activity was demonstrated in a Hantaan virus antigen prepared from infected suckling mouse brain by sucrose-acetone extraction. Hemagglutination of goose erythrocytes was pH dependent and was optimal at pH 6.0-6.2. Immunofluorescent and hemagglutination-inhibiting antibodies were significantly correlated in 80 human and 13 animal sera. Hemagglutination-inhibiting antibody was present in some patients 20 years after the onset of hemorrhagic fever with renal syndrome. The hemagglutination inhibition test was useful for confirming that an insectivore, Suncus murinus, may be an animal reservoir host of a Hantaan-like virus.

Background: Pulmonary carcinosarcomas (PCSs) are a heterogeneous group of non-smallcell lung carcinomas (NSCLCs) with aggressiveness and a poor prognosis. Although genetic mutations of some common lung cancer subtypes have been extensively studied, the molecular characteristics of PCSs and the existence of abnormal target genes are unknown. Methods: In this study, the clinical and molecular characterization in 3 pulmonary sarcomatoid carcinomas (PSCs) were presented using microscope analysis and next-generation sequencing (NGS) analysis. Results: The results revealed a carcinosarcomas subtype presenting squamous cell carcinoma and sarcoma components in all 3 cases. NGS analysis showed that 182, 316 and 230 shared mutations were detected between sarcoma and lung carcinoma from 3 patients. Two identical alterations in two genes (CSMD3 and RYR3) that were all shared by the two components in 3 patients. Tumor suppressor gene TP53 (5/6, 83%) showed the highest mutation frequency for driver genes here. Additionally, we focused on an LYST mutation which was mainly present in the sarcoma components. Moreover, the clonal evolution and signature analysis confirm that lung squamous cell carcinoma and sarcoma in each PCS patient may have come from a common ancestor, and mutagenesis was possibly related to indirect effects of tobacco, age or other unknown factors. Conclusion: Our results indicate that genetic analysis and molecular targeted therapy are necessary for the identification and treatment of these rare lung tumors. CSMD3 and LYST, as common mutation genes, may be a potential therapeutic target in PCS.

No abstract

No abstract